Oxytocic Pharmaceuticals Market

Key Points Covered In Oxytocic pharmaceuticals Market Research

• Market Estimates And Forecast 2021 - 2031
• Key drivers and restraints impacting the  market growth
• Segment wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Brand share and Market share Analysis
• Key Product Innovations and Regulatory Climate
• COVID-19 Impact on Oxytocic Pharmaceuticals Market And How to Navigate
• Recommendations on Key Winning Strategies

Oxytocic Pharmaceuticals Market Future Outlook for 2021-2031 vs Historic Sales

Improvements in newer oxytocic pharmaceuticals through licensing agreements will drive sales of the market over the forecast period. Besides this, expanding usage of Antepartum oxytocin injection for improvement in uterine contractions will positively influence the demand outlook for oxytocic pharmaceuticals.

With competition expected to soar in the coming years, manufactures are focusing on adopting strategies such as new product innovations, agreements and expansions to enhance their product portfolio.

Download a Comprehensive Report Snapshot

For instance, in 2020, Iconovo announced its new developmental agreement with Monash University for production of inhaled oxytocin ICOone. The agreement allows Monash a complete global right to employ ICOone with oxyyocin to inhibit postpartum haemorrhage in women giving birth. This development aids in enhancing Iconovo’s industrial experience and leverages to use its inhalation experience in the upcoming projects. 

Coupled with this, mergers and acquisitions remain a key strategy among market players. For instance, in 2020, Tonix Pharmaceuticals announced a licensing deal with Katana Pharmaceuticals for augmenting the use of its intranasal potentiated oxytocin drug to cure metabolic disorders such as obesity, diabetes and insulin resistance.

Post-partum Haemorrhage to Lead Oxytocic Pharmaceuticals Market

The post-partum haemorrhage segment was estimated to account for more than 75% market share of the global oxytocic pharmaceuticals market by the end of forecast period and is expected to gain more than 200 BPS in its market share by 2026. The post-partum haemorrhage segment is expected to register high Y-o-Y growth during the forecast period and is projected to remain the dominant segment during the forecast period.

Labour Induction during Childbirth Is Likely To Boost Post-Partum Haemorrhage Pharmaceuticals

Increasing childbirth using labour induction proves to be driving factor for the post-partum haemorrhage condition. There are certain situations – for instance, pre-eclampsia – where continuing the pregnancy is dangerous to the mother, or there are instances where women are uncomfortable, sore and tired. In such cases, labour is induced for convenience rather than medical reasons. However, labour induction increases the chances of post-partum haemorrhage.

According to the World Health Organization, the rate of labour induction in developing countries is lower; but in developed countries, the rates are relatively high, which is creating a positive impact on the post-partum haemorrhage segment. Another factor which is likely to fuel the revenue growth of the post-partum haemorrhage segment is the increasing age of mothers. Older and heavier women and women who are smokers are more likely to bleed heavily after delivery.

The ratio of getting pregnant after a certain age in life has increased in almost all the regions across the globe and this is creating robust development in the global oxytocic pharmaceuticals market, and specifically in the post-partum haemorrhage segment.

Demand in Africa Likely to Increase

The post-partum haemorrhage segment is the most attractive segment by indication in the North America oxytocic pharmaceuticals market, with a market attractiveness index of 3.9 estimated during the forecast period. In the Latin America region, the post-partum haemorrhage segment is estimated to reach a market attractiveness index of 3.7 due to increasing adolescent pregnancies. A majority of these pregnancies occur in Brazil in Latin America.

An increase in labour induction procedures in the region is responsible for positioning post-partum haemorrhage as the most attractive indication segment. The MEA region represents a higher prevalence of post-partum haemorrhage among all the regions owing to lack of proper nutrition to pregnant women. Africa’s contribution to the prevalence of post-partum haemorrhage in the MEA region is on the higher end, owing to a lack of healthcare infrastructure and awareness regarding pregnancy related aspects among African women.

Prevalence of post-partum haemorrhage is as high as 25.7% in African countries and 8.5% in Asian countries. In China, the post-partum haemorrhage segment is anticipated to record a market attractiveness index of 3.8 during the forecast period. A large pool of population and China’s altered single child policy to two children policy may likely increase the incidence of post-partum haemorrhage. 

Opportunities in the Global Oxytocic Pharmaceuticals Market

Companies functioning in the global oxytocic pharmaceuticals market can reap larger market revenue from untapped markets in Asia and Africa where the prevalence of post-partum haemorrhage is on the higher side in comparison with other regions. Imparting awareness pertaining to pregnancy among the women in these regions can help create more market opportunities for existing as well as new entrants in the global oxytocic pharmaceuticals market.

Key Questions Answered in the Report

• How much is the Oxytocic Pharmaceuticals Market Worth?

  The global oxytocic pharmaceuticals market will reach a valuation of US$ 98.60 Mn in 2021, rising at a CAGR of 7.74% between 2021 and 2031.

• At What Rate did the Oxytocic Pharmaceuticals Market Grow in the Last Five Years?

  The oxytocic pharmaceuticals market exhibited growth at 3.60% CAGR between 2016 and 2020.

• What is the Market Share of Top Players in Oxytocic Pharmaceuticals Market?

  The combined market share of tier-1 players stood at 35-40% of the overall market.

• What is the North America Oxytocic Pharmaceuticals Outlook?

  The demand for oxytocic pharmaceuticals is expected to grow at 9% in North America between 2021 and 2031.

• At What Percentage will Germany drive sales of Oxytocic Pharmaceuticals in European region?

  In 2021, Germany will account for approximately 31% share of oxytocic pharmaceuticals in the European region.

• Which are top 5 Countries driving Oxytocic Pharmaceuticals demand?

  China, India, U.S., Japan, and GCC Countries are driving demand for oxytocic

• What is driving demand for Oxytocic Pharmaceuticals Market?

  Increasing labour induction procedures, growing prevalence of PPH andprequalification from WHO will drive the sales of Oxytocic Pharmaceuticals.

• What are the Key Trends of Oxytocic Pharmaceuticals Market?

  Highly fragmented market and increasing licensing activities are key trendsobserved in the market.

• What are the Key Statistics for Oxytocic Pharmaceuticals Market in Japan?

  Japan accounts for 2.6% share in the global oxytocic pharmaceuticalsmarket.

The Report Segments the Market into Five Sections:

By Indication

• Abortion Induced Incomplete
• Inevitable Abortion
• Post-partum Haemorrhage
• Labour Induction
• Labour Arrest

By Route of administration

• Intravenous Infusion/Injection
• Intramuscular Injection

By Source of Origin

• Natural Oxytocin
• Synthetic Oxytocin Derivative

By End-User

• Hospitals
• Maternity clinics

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan and China (APEJC)
• Japan
• China
• Middle East & Africa (MEA)